Risk of death following application of paclitaxel‐coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta‐analysis of …
Background Several randomized controlled trials (RCT s) have already shown that
paclitaxel‐coated balloons and stents significantly reduce the rates of vessel restenosis and …
paclitaxel‐coated balloons and stents significantly reduce the rates of vessel restenosis and …
Drug-coated balloon therapy in coronary and peripheral artery disease
Nonstent-based local drug delivery during percutaneous intervention offers potential for
sustained antirestenotic efficacy without the limitations of permanent vascular implants …
sustained antirestenotic efficacy without the limitations of permanent vascular implants …
Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK) a randomized trial in diabetic patients with critical limb …
Background—The 1-year restenosis rate after balloon angioplasty of long lesions in below-
the-knee arteries may be as high as 70%. Our aim was to investigate the efficacy of a …
the-knee arteries may be as high as 70%. Our aim was to investigate the efficacy of a …
Management of critical limb ischemia
S Kinlay - Circulation: Cardiovascular Interventions, 2016 - Am Heart Assoc
Critical limb ischemia (CLI) is a clinical syndrome of ischemic pain at rest or tissue loss, such
as nonhealing ulcers or gangrene, related to peripheral artery disease. CLI has a high short …
as nonhealing ulcers or gangrene, related to peripheral artery disease. CLI has a high short …
Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for …
Objectives: This study sought to compare paclitaxel-eluting balloon (PEB) with conventional
percutaneous transluminal angioplasty (PTA), followed by systematic implantation of a self …
percutaneous transluminal angioplasty (PTA), followed by systematic implantation of a self …
Drug-coated balloon versus standard balloon for superficial femoral artery in-stent restenosis: the randomized femoral artery in-stent restenosis (FAIR) trial
Background—Drug-coated balloon angioplasty (DCBA) was shown to be superior to
standard balloon angioplasty (POBA) in terms of restenosis prevention for de novo …
standard balloon angioplasty (POBA) in terms of restenosis prevention for de novo …
Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal …
F Liistro, P Angioli, I Porto, L Ricci… - Journal of …, 2014 - journals.sagepub.com
Purpose To test the ability of a drug-eluting balloon (DEB) to reduce recurrent in-stent
restenosis (ISR) in diabetic patients with femoropopliteal stents. Methods A prospective all …
restenosis (ISR) in diabetic patients with femoropopliteal stents. Methods A prospective all …
Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized …
Objectives: This study sought to report the results of a prospective randomized controlled
trial comparing paclitaxel-coated balloons (PCB) versus drug-eluting stents (DES) in long …
trial comparing paclitaxel-coated balloons (PCB) versus drug-eluting stents (DES) in long …
[HTML][HTML] The diagnosis and treatment of peripheral arterial vascular disease
H Lawall, P Huppert, C Espinola-Klein… - Deutsches Ärzteblatt …, 2016 - ncbi.nlm.nih.gov
Background In peripheral arterial occlusive disease (PAOD), arterial stenosis or occlusion
impairs perfusion in the territory of the distal portion of the aorta and the iliac and leg …
impairs perfusion in the territory of the distal portion of the aorta and the iliac and leg …
Drug-coated balloon versus plain balloon angioplasty for the treatment of femoropopliteal artery disease: an updated systematic review and meta-analysis of …
Objectives: This study sought to assess the risk of target lesion revascularization (TLR) and
all-cause death at 12 months and at the maximum available follow-up. Secondary objectives …
all-cause death at 12 months and at the maximum available follow-up. Secondary objectives …